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Abstract Assessing theresultsofmoderncystic fibrosis (CF)-care andestimating the futurepopulation anditsdemo-
graphy is importantto evaluate the treatment regimens and to calculate the future needs of health-care resources.This
paperupdatespreviousincidence calculations.It assesses theresults ofmodernCF-care intermsof survival andchanging
demographyin Sweden.Theincidence of CFin Swedenwascalculated as1/5600 live-births.Ofthe CF-population alive in
1999,45%were18 yearsold.Themeanannualmortalityrate since1991was 0?9% (70?4) andthemedianage atdeath 26
years (range 0--72).Ofthose born1991,95%were estimated to survive their 25thbirthday.The incidence of CF in Swe-
denislow.Modern CF-care in Sweden showsgoodresults.The CF-populationisgrowingrapidlyandthe adultpartofthe
population will soon be larger than the paediatric.Continuously adapted resources are required to assure the future
treatmentquality, especially for the growingadult CF-population.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1329, available online athttp://www.idealibrary.comonINTRODUCTION
The importance of centralised and preventive, aggres-
sive treatment in cystic ¢brosis (CF)-care is emphasised
in discussions (1^7). The di¡erent parts of the multifa-
ceted CF-treatment are continuously developing, result-
ing in improved clinical status and survival (1^11).
However, the results of the care di¡er a lot from one
country to another (10) and sometimes from centre to
centre (6).
Assessing the results of modern CF-care and estimat-
ing the future population and its demography is
important to evaluate the treatment strategies
and to calculate the future needs of health-care
resources (7,12).
This paper includes all known dead and alive Swedish
CF-patients until 1999. The updated incidence of CF in
Sweden is discussed as well as the median age at death
and themean annualmortality rate for di¡erent periods
since 30 years have been recorded. Survival is predicted
and the size as well as the demography of the future CF-
population in Sweden are estimated.Received 7 June 2001, accepted in revised form 6March 2002.
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Patients
The population studied includes all known dead and alive
CF-patients in Sweden until 1999. The CF-diagnosis was
based on clinical symptoms consistent with the U.S.
Consensus document1998 (13). All four CF-centreswith-
in the country as well as the departments of paediatrics,
respiratory medicine and infectious diseases at all local
hospitals were contacted both by letter and telephone.
They were asked to report presently and previously
knownCF-patients.The Swedish Cystic Fibrosis Associa-
tionwas initiatedin1969 andhas savedall its lists ofmem-
bers. Information from these lists of present and past
members was used. Copies of all death certi¢cates
where cystic ¢brosis or its synonyms were registered
both in words and codes were collected from the Na-
tional Bureau of Statistics from 1971 when the disease
started to be registered.
Data/material
All individuals were reported by date of birth, sex and
initials in order to eliminate duplications. In doubtful si-
tuations, the di¡erent units were contacted and sus-
pected duplications were sorted out. Information about
the date of diagnosis, date of death, heart/lung, lung or
liver transplantation and patients on waiting lists for
transplantation were collected. The few death certi¢-
cates where either diagnosis or code did not ¢t were
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tients or not by doctors responsible for the CF-care at
the regional CF-centre. A coded questionnaire was dis-
tributed to all individuals alive, except those who had
had the diagnosis within the last year.
Data analysis
Calculations of incidence were limited to the 1980^89
period since several CF-patients born after 1989 may
not as of yet have had a CF-diagnosis. A number of
youngsters and adults with CF born during that period
but expectednot yet to have a CF-diagnosis were added.
That number was based on ¢ndings in the study. Statisti-
calmethodsusedwere cumulated1-year survival, logistic
regression and Cox regression.Mortality ratewas calcu-
lated as the number of deaths per100 individuals alive at
the end of each year.The cumulative 1-year survival was
based on those individuals who had lived to a certain age
and who had been diagnosed then or earlier. The 1-year
survival was then calculated as the proportion of how
many survived the following year.The cumulative survi-
val was calculated as the product of the survival rates
during consecutive years. In the calculations, patients
were divided into cohorts based onyear of birth.The es-
timated number of patients extrapolated to 2011 was
based on linear trends between 1980 and 1997 and di-
vided into children and adults. Predicted survival to 2016
was extrapolated from an estimated constantmortality
rate for all ages after the ¢rst year of living.
RESULTS
Patients
All CF-centres and all hospital departments asked to
provide information replied.The questionnaire distribu-
ted to the patientswas answeredby 74%.The total num-
ber of known CF-patients in Sweden in1999 was 628.Of
these,475 individualswere alive at the time for the study,
0^63 years old (51%male). Since1971,153 individuals with
CF have died, 0^72 years old (45%male).Twenty-nine pa-
tients have had transplantation; 24 lung, 4 heart/lung and
1 liver. Median age at the time for lung or heart/lung
transplantation was 28 years (range11^46).Three indivi-
duals were on the waiting list for lung transplantation.
Among all the CF-adults, 22% (31 females and 17 males)
had children, of whom 5 had adopted their child(ren).Of
the adults who had ¢nished school/education, 75% were
working part- or full-time.
Of all the 475 CF-patients alive, 97% were in contact
with a CF-centre of whom 54% were seen solely at a
CF-centre and 43% had their care shared between their
home hospital and a CF-centre.The remaining 3% were
seen at their home hospital only.Age at diagnosis
Median age when symptoms appeared was 1 month
although symptoms appeared as late as at 58 years of
age.Median age at diagnosis was 9 months (0^64 years).
Of all the CF- patients alive, 59% had their diagnosis by
the age of 1 year, 25% between 1 and 5 years and 6%
418 years old. Of those alive and 435 years old, 12%
had their diagnosis by the age of 1 year and 50% o18
years old.
Incidence
So far, 162 individuals of all live-born from 1980 through
1989 have been diagnosed with CF.This gives a mean an-
nual crude incidence of1/6500 (range1/4500^1/10500). In
accordance with study ¢ndings, the crude incidence was
compensated by adding 6% expected to have their diag-
nosiswhen older than18 years and 4% to have their diag-
nosis when11^18 years old.The mean incidence of CF in
Sweden was thereby calculated to be approximately 1/
5600 or 1.8/10 000 live-births. Mean carrier number in
Swedenwould then be1/37.
Survival and estimatedpopulation
The median age of CF-patients alive was 16 years (Fig.1)
and themean age was18 (712) years.The oldest patient
was 63 years old. At the time of the study, 45%were18
years old and10% were435 years old (Fig.1).The mean
annual mortality rate since1991was 0.9% (70.4), corre-
sponding results speci¢ed for di¡erent periods are pre-
sented in Fig. 2. This ¢gure also shows the
corresponding median age at death, which since 1991
was 26 years (range 0^72). The predicted survival for
the di¡erent groups until year 2016 are shown in Fig. 3;
95% of the patients born in1991or later are predicted to
become 25 years old. Provided the number of live-
births remains the same, the CF-population will have in-
creasedwith 36% by the year 2011.
DISCUSSION
TheDF508 is generally associatedwith amore aggressive
disease.The frequencyofDF508mutations amongCF-al-
leles within the Swedish CF-population alive is 68.3%,
47% of the patients are homozygous for DF508 (14).Two
other mutations are fairly common, 394delTT 8.5% and
3659delC 7.9% (14). The DF508 frequency in our popula-
tion is comparable to that in other Europeanpopulations
studied where the DF508 frequency is reported to be
54^88% (15).
Another factor associatedwith severe clinical disease
is pancreas dysfunction. Of the Swedish CF-population,
87% within the paediatric and 90% within the adult part
received pancreatic enzyme substitution (national
DEMOGRAPHYOFSWEDISHCFCOMMUNITY 683CF-registry, unpublished results). This is comparable to
most CF-populations (15,16). However, a compilation of
data enrolled in the European Epidemiologic Registry of
Cystic Fibrosis (ERCF) in1996 including 6858 CF-patients
from eight countries, showed 93^97% within di¡erent
sub-groups o13 years old and 78^94% within di¡erent
sub-groups418 years old to be treated with pancreatic
enzymes (17).Data from the same registry in1997 includ-
ing11749 CF-patients fromnine countries showed 97% of
the o18 years old and 95% of the 418 years old to be
treated with pancreatic enzymes (18). To what extent
these data are representative remains to be seen, since
the number of patients included in the ERCF at the time
for the second compilation was estimated to be about
half of the whole CF-population in the nine countries
(18). In our population, the paediatric group received
pancreatic enzyme substitution to a less degree than0
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the early diagnosing that could result in relatively many
of those not needing substitution being included in the
paediatric group. This in combination with the fact that
some adults who never received substitution as children
but who have had gastrointestinal problems as adults
have had less symptoms once starting on substitution.
Added to this is the fact that di¡erences in diagnostic cri-
teria when it comes to need for pancreatic enzyme sub-
stitution can vary andmake comparisons di⁄cult (18).
Chronic colonisation of Pseudomonas aeruginosa (PA) is
generally associatedwith amore aggressive lung disease.
Of our CF-population 48% was chronically colonised
with PA: 36% of the paediatric and 62% of the adult
population (national CF-registry, unpublished results).
This is comparable to the 45% of a Danish CF-population
(19). A study including 63% of the North American0
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684 RESPIRATORYMEDICINECF-population reported 61% chronically colonised with
PA (16). Of the adults taken care of ¢rst by a paediatric
and then an adult CF-centre in the U.K. 90% were re-
ported chronically colonisedwith PA (4).
The incidence calculations were based on the number
of diagnosed patients born during 1980^89.This 10-year
period was chosen since the disease was commonly
known within health care by then and most individuals
with CF born during these years ought to have been
identi¢edbynow.Ourcalculatedincidence forCF in Swe-
den, of approximately 1/5600, is lower than what has
been calculated for theU.S.A. (9) and less or in the lower
span of what is calculated for the Western Europe as a
whole (2,3,5,8). It is also less than what was calculated
for Sweden in 1982 (20) but more than in 1962 (21).One
can only speculate in the results of the two Swedish stu-
dies carried out with a 20-year interval. One probable
reason is under-diagnosing in the 1962 data. All data are
not presented in the study published in 1982, which
makes the discrepancy from the current results di⁄cult
to comment.
Of the whole Swedish CF-population, 6% were diag-
nosed after age18 years.Most patients with late diagno-
sis had amilder disease, but thiswas not always the case.
Therewere patients whowere diagnosed as respiratory
insu⁄cient adults. Continuous information and remin-
ders about CF within adult health care of di¡erent disci-
plines remains important.
The proportion adults (18 years old) within the
SwedishCF-populationhas increased to 45% (Fig.1), com-
pared to 32% in 1986 (22). Data from the European CF-
registry 1997 including 12 447 individuals with CF from
Austria, Belgium, Denmark, France, Germany, Ireland,
Netherlands, Sweden and United Kingdom showed 29%
of thepopulation to be18 years old (11). Among theCF-
patients included in the Cystic Fibrosis Foundation
(U.S.A.) Registry 2000, about1/3 were adults (23).
Data from 114 accredited CF-centres in the U.S.A. in
1990 showed amortality rate of 2,3% (9) and themortal-
ity rate for the U.K.CF-population was 2.1% during1995
(3). Frederiksen et al. have reported the best results so
far when they showed an annual mortality rate of 0^
1,2% during 1989^93 among Danish CF-patients treated
at the Copenhagen CF-centre (75% of thewhole Danish
CF-population) (2).Themean annualmortalityrate (since
1991, 0.9%) found in this study which compiles all Swedish
CF-patients canvery wellbe compared to theDanish re-
sults (Fig. 2). Another parameter of interest when asses-
sing treatment e¡ects for a whole population is median
age at death (10).Themedian age at death in our popula-
tion since 1991 was 26 years (Fig. 2), which is relatively
high in comparison to other reports (2,3,8^11).
The fact that fewer CF-patients die early in life make
long-time survival predictionsmore andmore di⁄cult to
carry out (3). We decided to make a short prediction
which showed 95% of the cohort born 1991 predictedto survive their 25th birthday (Fig. 3).The survival prob-
ability in Denmark for a child bornwith CF during1989^
93 and treated at a CF-centre was estimated to be 80%
reaching its 45thbirthday (2).For patients included in the
Cystic Fibrosis Foundation (U.S.A.) Registry 2000, the
median survival was predicted to the early 30s (23). Ca-
nadian data from 1998 showed predicted survival till
adulthood of 80% (24). The largest di¡erence and im-
provementin our study is seenduring the ¢rst year of life
(Fig. 3), as has been shown by others as well (7).This dif-
ference is probably due to the modern CF-care dealing
withmeconiumileus andmalnutrition in amoree¡ective
way.The survival rate after the ¢rst year of life, or during
the last ten years, might be more informative when it
comes to evaluating standards for CF-treatment. Di¡er-
ences comparablemight then be focusing on themodern
CF-care dealing with nutritional factors, pulmonary hy-
per secretion, infections and physical exercise.
It has been shown thatmanagementof CF by specialist
teams in centres produce better clinical outcome para-
meters (1,4). The proportion patients in contact with a
CF-centre is big in our population (97%). A large part of
the population, 43%, also have a regular contact with
their home hospital, shared care. Shared care is said to
be appreciated by both the patients living far from a CF-
centre and the home hospital sta¡.
Considering the high median age at death, the major
increase of the CF-population will be in the adult group
(18 years), which in a couple of years is predicted to be
larger than thepaediatric group.TheCF-adultswill prob-
ably be su¡ering from ordinary health-care problems
with growing age at least to the same extent as people
without CF (3). It still remains to be seen as to what CF
itself and the treatment does to the body in the long run
(25). It is of great importance that resources are kept up
with the growing adult population, otherwise the im-
proving survival rate cannot be expected to continue
(4,7,12).
CONCLUSION
The incidence of CF in Sweden is relatively low. Interna-
tionally compared, the annual mortality rate has been
low since 1991 and the median age at death high. For pa-
tients born 1991 predicted survival at age 25 years is
95%.We credit the improving survival to the centralised,
modern, active CF-care in Sweden.The improving survi-
val is leadingus to a rapidlygrowingCF-populationwith a
proportion18 years old that soon outnumber the pae-
diatric patients.This demographic transitionwill increase
the demands on the adult CF-health care.
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